FAB Pharma raises series A to fund former Mutabilis programme
This article was originally published in Scrip
Executive Summary
FAB Pharma, a corporate spin-out from the former French biotechnology company Mutabilis, has raised a series A round of €2.3 million led by the French venture capital firms CDC Innovation and Bioam Gestion. The US-based hedge fund Redmile Group also participated.